Stephen B. Hanauer mainly focuses on Internal medicine, Surgery, Gastroenterology, Crohn's disease and Placebo. Internal medicine is a component of his Ulcerative colitis, Clinical trial, Inflammatory bowel disease, Adalimumab and Gastrointestinal agent studies. His Surgery research integrates issues from Vedolizumab and Adverse effect.
His studies deal with areas such as Infliximab, Certolizumab pegol, Crohn's Disease Activity Index, Azathioprine and C-reactive protein as well as Gastroenterology. The concepts of his Crohn's disease study are interwoven with issues in Severity of illness, Rheumatoid arthritis, Fistula and Dosing. He interconnects Induction chemotherapy, Clinical endpoint, Randomized controlled trial and Management of Crohn's disease in the investigation of issues within Placebo.
His primary areas of investigation include Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease. His work deals with themes such as Placebo and Surgery, which intersect with Internal medicine. His Placebo research incorporates themes from Adverse effect and Clinical endpoint, Randomized controlled trial.
His research investigates the connection between Gastroenterology and topics such as Azathioprine that intersect with issues in Mercaptopurine. Stephen B. Hanauer has included themes like Adalimumab, Certolizumab pegol, Clinical trial and Immunology in his Crohn's disease study. His Ulcerative colitis research includes elements of Colonoscopy, Colorectal cancer, Colitis and Dysplasia.
His scientific interests lie mostly in Internal medicine, Gastroenterology, Inflammatory bowel disease, Ulcerative colitis and Crohn's disease. Stephen B. Hanauer regularly links together related areas like Placebo in his Internal medicine studies. In his study, which falls under the umbrella issue of Placebo, Infliximab is strongly linked to Surgery.
His work carried out in the field of Gastroenterology brings together such families of science as Disease activity, Pharmacokinetics, Calprotectin, Ozanimod and Colonoscopy. As part of one scientific family, Stephen B. Hanauer deals mainly with the area of Inflammatory bowel disease, narrowing it down to issues related to the Intensive care medicine, and often Thiopurine methyltransferase. The various areas that Stephen B. Hanauer examines in his Crohn's disease study include Adalimumab and Chronic abdominal pain.
Stephen B. Hanauer mainly investigates Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology. His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Surgery. His Inflammatory bowel disease research integrates issues from Therapeutic drug monitoring, Immunology, Intensive care medicine, Radiology and Colorectal cancer.
His Ulcerative colitis research is multidisciplinary, incorporating elements of Irritable bowel syndrome, Colitis and Retrospective cohort study. The concepts of his Crohn's disease study are interwoven with issues in Post-hoc analysis, Abscess, Azathioprine and C-reactive protein. Stephen B. Hanauer combines subjects such as Pharmacokinetics, Crohn's Disease Activity Index, Placebo-controlled study, Double blind and Colonoscopy with his study of Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Yasunori Ogura;Denise K. Bonen;Naohiro Inohara;Dan L. Nicolae.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Targan;Hanauer Sb;van Deventer Sj;Mayer L.
The New England Journal of Medicine (1997)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)
Infliximab for the treatment of fistulas in patients with Crohn's disease.
D.H. Present;P.J. Rutgeerts;S.R. Targan;S.B. Hanauer.
The New England Journal of Medicine (1999)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns.
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Simon Lichtiger;Daniel H. Present;Asher Kornbluth;Irwin Gelernt.
The New England Journal of Medicine (1994)
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer.
The New England Journal of Medicine (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer.
The New England Journal of Medicine (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: